Il primo studio dedicato: Hansen 2024 A maggio 2024 un gruppo danese ha pubblicato su eClinicalMedicine il primo studio randomizzato disegnato apposta per valutare gli effetti di semaglutide sullosso
The Evidence Behind the Enthusiasm A March 2025 article in Pediatricsc titled GLP-1 Receptor Agonists in Pediatric and Adolescent Obesity, explores wtheuse of these medications for children, heir potential side effects, efficacy, and mental health considerationsall of which must be considered by physicians and nutritionists
These included changes in body weight, waist circumference, waist to height ratio (WHtR), BMI category, and cardiometabolic risk factors such as blood pressure, cholesterol, blood fats, glucose measures and hs-CRP
If youre trying to understand how it fits into the current landscape of weight loss medications, and how it stacks up against GLP-1 options like semaglutide and tirzepatide, heres a clear-eyed look at what the evidence actually shows